

6. Harwell TS, McDowell JM, Moore K, Fagot-Campagna A, Helgerson SD, Gohdes D. Establishing surveillance for diabetes in American Indian youth. *Diabetes Care* 2001;24:1029–32.
7. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 2003;26(suppl 1):S5–S20.
8. U.S. Department of Health and Human Services. User population estimates 1995 to 1997. Available at <http://www.ihs.gov/facilitieservices/areaoffices/billings/stats/population.asp>.
9. Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM. Identifying persons with diabetes using Medicare claims data. *Am J Med Qual* 1999;14:270–7.
10. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. *Diabetes Care* 2002;25:512–6.

## Investigation of a Ricin-Containing Envelope at a Postal Facility — South Carolina, 2003

On October 15, 2003, an envelope with a threatening note and a sealed container was processed at a mail processing and distribution facility in Greenville, South Carolina. The note threatened to poison water supplies if demands were not met. The envelope was isolated from workers and other mail and removed from the facility, and an investigation was begun. On October 21, laboratory testing at CDC confirmed that ricin was present in the container. To assess the human health effects related to possible ricin exposure, the South Carolina Department of Health and Environmental Control (SCDHEC) and CDC interviewed all workers at the postal facility and initiated statewide surveillance for illness consistent with ricin exposure during October 15–29. On October 22, the facility was closed for a detailed epidemiologic and environmental investigation. This report summarizes the results of the investigation, which found no evidence of environmental contamination and no cases of ricin-associated illness. Clinicians and public health officials should be vigilant for illnesses suggestive of ricin exposure.

SCDHEC asked emergency departments, clinicians, health departments, and the local postal facility to report any cases consistent with ricin exposure to the state health department and CDC. State poison control center records and intensive care unit charts at seven hospitals in the Greenville, Spartanburg, and Anderson areas were reviewed daily for illness consistent with ricin exposure. A CDC medical toxicologist and state and local health department epidemiologists interviewed all 36 workers at the postal facility to identify ricin-related illnesses.

CDC conducted environmental assessment and sampling at the postal facility, consisting of 70 wipe samples and five surface dust samples (collected by sampling pumps and sampling filter media). Wipe samples were obtained by using Dacron™ swabs moistened with sterile buffered solution and were collected from specific surfaces in the facility, including storage bins, surfaces, conveyor belts, and sorting tables that had been in contact with the letter. All environmental samples were analyzed at CDC and were negative for ricin.

No workers had illness suggestive of ricin exposure. Statewide surveillance did not identify any cases of ricin-associated illness. However, two cases of multisystem organ failure and several nonspecific illnesses, which likely were detected because of increased surveillance and reporting, were investigated within the state. The postal facility was reopened after 1) all workers who had worked at the facility since the package was discovered had been contacted and confirmed to be well and 2) environmental samples for ricin were negative. As of November 19, no ricin-associated cases had been identified.

Regional and national surveillance for illness consistent with ricin poisoning was initiated through an ongoing collaboration between CDC, ATSDR, and the American Association of Poison Control Centers' Toxic Exposure Surveillance System (TESS). Surveillance for potential cases was accomplished by monitoring call volumes at 62 of the 63 poison control centers in the United States for clinical effects consistent with ricin poisoning and for cases referring to the specific product code ("Contaminated Water") because water had been stated as a potential target by the note in the package. During October 15–29, approximately 97,000 human exposure calls were reported to TESS. No ricin-associated syndromes or events were identified.

**Reported by:** J Gibson, MD, D Drocik, MSPH, T Fabian, MD, S Brundage, MD, L Ard, N Fitzpatrick, MPH, W Moorhead, JD, South Carolina Dept of Health and Environmental Control. M Schwartz, MD, E Kilbourne, MD, ATSDR; J Schier, MD, M Patel, MD, M Belson, MD, C Rubin, DVM, Div of Environmental Hazards and Health Effects, J Osterloh, MD, Div of Laboratory Sciences, S Deitchman, MD, National Center for Environmental Health; Max Kiefer, CIH, National Institute for Occupational Safety and Health, R Meyer, PhD, Bioterrorism Preparedness Response Program, National Center for Infectious Diseases, CDC.

**Editorial Note:** The Federal Bureau of Investigation (FBI) and local law enforcement authorities are conducting an investigation to identify the illegal source of this toxin. However, until a source is identified and eliminated, health-care providers and public health officials must consider ricin to be a potential public health threat and be vigilant about recognizing illness consistent with ricin exposure.

Ricin is a biologic toxin derived from the castor bean plant *Ricinus communis* (1,2) (Box). Ricin is one of several toxalbumins that exert toxicity by inhibiting protein synthesis in eukaryotic cells (1,2). Several instances of ricin procurement for use as a terrorist weapon have been documented (3–5).

Routes of exposure to ricin include ingestion, inhalation, parenteral, dermal, or ocular; however, systemic toxicity has been described in humans only after ingestion or injection. Ricin is considered to be a much more potent toxin when inhaled or injected compared with other routes of exposure. Ricin poisoning is not contagious, and person-to-person transmission does not occur.

Processed and purified ricin can be disseminated by aerosol, contamination of food or water, or injection (1,6). Ricin particles of <5 microns have been used for aerosol dispersion in animal studies and can stay suspended in undisturbed air for several hours. Resuspension of settled ricin from disturbed surfaces also might occur.

Data about the effects of ricin poisoning on humans are limited. Because ricin poisoning might resemble typical gastroenteritis or respiratory illness, it might at first be difficult to discern from other illnesses. For this reason, suspicion of cases should occur in conjunction with epidemiologic clues suggestive of chemical release (e.g., an unusual increase in the number of patients seeking care or unexpected progression of symptoms in a group of patients) or a credible threat of chemical release in the community (7). As in the instance described in this report, health departments should inform clinicians, poison control centers, and other health departments rapidly of any emerging evidence of ricin exposures.

## Clinical Manifestations

**Ingestion:** No reports of illness after ingestion of purified ricin toxin have occurred. Signs and symptoms from oral exposure to purified ricin are presumed to be similar to reports of illness after castor bean mastication and ingestion (6). However, reports of illness from castor bean ingestion also are not well documented. Toxicity can range from mild to severe and can progress to death (6). Mild illness can include nausea, vomiting, diarrhea, and/or abdominal cramping. Onset of gastrointestinal symptoms typically occurs in 1–4 hours (6). In moderate to severe illness, gastrointestinal symptoms (i.e., persistent vomiting and voluminous diarrhea [bloody or non-bloody]) typically lead to substantial fluid loss, resulting in dehydration and possibly hypovolemic shock (6). In severe poisoning, liver and renal failure and death are possible.

## BOX. Background, diagnosis, treatment, and prevention and reporting of ricin poisoning

### Background

- Ricin is a toxin derived from the castor bean plant *Ricinus communis*.
- Poisoning can occur via ingestion, inhalation, or injection.
- Ricin poisoning can have a presentation similar to gastroenteritis or respiratory illnesses.
- Epidemiologic clues include increased number of patients seeking care, unexpected progression of symptoms, or a credible threat of ricin release in the community.
- Person-to-person transmission does not occur.
- Ricin has been procured for use as a terrorist weapon.
- Inhalation and injection are considered to be the most lethal routes of exposure.

### Clinical Findings

- Ingestion: Mild poisoning can result in nausea, vomiting, diarrhea, and/or abdominal pain. In moderate to severe poisoning, gastrointestinal symptoms can progress (4–36 hours) to hypotension, liver and renal dysfunction, and possibly death.
- Inhalation: Illness can occur within 8 hours and include cough, dyspnea, arthralgias, and fever, and can progress to respiratory distress and death.
- Injection: Initial (i.e., ≤6 hours) symptoms can include generalized weakness and myalgias; progression of illness (24–36 hours) can include vomiting, fever, hypotension, and/or multi-organ failure and death.

### Laboratory Testing

- No methods are available to detect ricin in biologic fluids.
- CDC and Laboratory Response Network laboratories conduct tests to detect ricin in environmental samples.

### Recommended Treatment

- Treatment is mainly supportive and includes intravenous fluid and vasopressors (e.g., dopamine) for hypotension.
- Activated charcoal should be administered to persons with known or suspected ricin ingestion if vomiting has not begun and airway is secure.
- Gastric lavage may be considered if ingestion has occurred in ≤1 hour.
- If a credible threat exists, patients with illness consistent with ricin poisoning should be observed for illness progression.
- The regional poison control center should be contacted for individualized care and further management.

### Prevention and Reporting

- All known or suspected cases of ricin exposure should be reported to the regional poison control center (1-800-222-1222) and local and state health departments.
- Clinicians, other health departments, and other poison control centers also should be alerted when ricin poisoning is suspected.

**Inhalational Exposure:** Data on inhalational exposure to ricin in humans are limited. Workers exposed to castor bean dust have described allergic reactions (e.g., nasal and throat congestion, eye irritation, hives, chest tightness, and wheezing) (8). Aerosol exposures to ricin can be followed within 4–8 hours by fever, chest tightness, cough, dyspnea, nausea, and arthralgias followed by diaphoresis (9).

**Parenteral Exposure:** In a single human trial evaluating low doses of intravenous ricin as a chemotherapeutic agent, influenza-like symptoms with fatigue and myalgias for several days were reported (1). Ricin injection in one case caused weakness within 5 hours, fever and vomiting within 24 hours, followed by shock and multi-organ failure, and death in 3 days (1).

## Management and Decontamination

Treatment for ricin toxicity is primarily supportive, including intravenous fluids, vasopressors, respiratory support, and cardiac monitoring. No specific antidotal therapy exists, and ricin cannot be removed by dialysis. Prophylactic vaccine and immunotherapy are not available (1). The same general guidelines for gastrointestinal decontamination employed for other ingested toxins should be applied to ricin (10). A single dose of activated charcoal should be administered as soon as possible if the patient is suspected of ricin ingestion and is not vomiting. The efficacy of gastric lavage is controversial but may be considered for known or suspected substantial ingestions if presentation to the hospital occurs within 1 hour of ingestion. Ipecac, whole bowel irrigation, and cathartics should not be used routinely for known or suspected ricin poisoning. Clinical presentations and their management can vary considerably. Clinicians are strongly advised to contact their regional poison control center immediately upon suspicion of a case of ricin exposure for guidance and further individualized management.

Skin decontamination for ricin exposure should be performed if a powder or similar substance is found on the patient, preferably in a designated area outside the main emergency department. Potentially exposed persons should be advised to wash their hands thoroughly with soap and water and refrain from any hand-to-mouth activities.

## Laboratory Detection

No methods are available for the detection of ricin in biologic fluids. Ricinine is a separate compound from ricin present in the castor bean and might be more feasible to monitor in persons exposed to ricin-containing plant material.

Preparations of ricin-containing substances and environmentally collected specimens can be tested for the presence of ricin by a time-resolved fluorescence immunoassay, available at CDC and member Laboratory Response Network state public health laboratories. In addition, CDC performs a polymerase chain reaction assay on similar type specimens that will detect the gene in the plant material that codes for the ricin protein. Several commercial handheld or test-strip detection devices are available, but the performance of these assays is unknown.

## Reporting

Suspected or known cases of ricin poisoning should be reported immediately to the regional poison control center (telephone, 1-800-222-1222) and to local or state public health agencies, which will report cases to other health departments, CDC, and other federal agencies.

## References

1. Franz DR, Jaax NK. Ricin toxin. In: Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: TMM Publications, 1997.
2. Olsnes S, Kozlov JV. Ricin. *Toxicon* 2001;39:1723–8.
3. U.S. Federal Bureau of Investigation. Counterterrorism Threat Assessment and Warning Unit. Terrorism in the United States, 1995: Renditions and Convictions of Suspected Terrorists. Washington, DC: U.S. Government Printing Office, 1995.
4. Cameron G. WMD terrorism in the United States: the threat and possible countermeasures. *The Nonproliferation Reviews* 2000;Spring:162–1794.
5. U.S. House of Representatives Subcommittee on Oversight and Investigations. Threatened Use and Possession of Biological Agents Hearing, 19 May 1999. Washington, DC: U.S. Government Printing Office, 1999.
6. Challoner KR, McCarron MM. Castor bean intoxication. *Ann Emerg Med* 1990;19:159–65.
7. CDC. Recognition of illness associated with exposure to chemical agents—United States, 2003. *MMWR* 2003;52:938–40.
8. Brugsch HG. Toxic hazards: the castor bean. *Mass Med Soc* 1960;262:1039–40.
9. U.S. Army Medical Research Institute of Infectious Diseases. USAMRIID's Medical Management of Biological Casualties Handbook, 4th ed. Fort Detrick, Maryland: U.S. Army Medical Research Institute of Infectious Diseases, 2001.
10. Chyka PA, Seger D. Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. *J Toxicol Clin Toxicol* 2000;38:721–41.



# MMWR<sup>TM</sup>

## Morbidity and Mortality Weekly Report

Weekly

November 21, 2003 / Vol. 52 / No. 46


### Primary and Secondary Syphilis — United States, 2002

After declining every year during 1990–2000, the rate of primary and secondary (P&S) syphilis in the United States increased in 2001. To characterize the epidemiology of syphilis in the United States, CDC analyzed national surveillance data for 2002\*. This report summarizes the results of that analysis, which indicate that the number of reported cases of P&S syphilis increased 12.4% in 2002. As in 2001, this increase occurred only among men, suggesting that this increase occurred particularly among men who have sex with men (MSM). For the 12th consecutive year, the number of P&S syphilis cases declined among women (Figure) and non-Hispanic blacks. These data suggest that although efforts to reduce syphilis among these populations have been effective, additional intervention strategies are needed to prevent syphilis among MSM.

CDC analyzed surveillance data for syphilis cases reported weekly to health departments nationwide in 2002. Data included each patient's county of residence, sex, stage of disease, race/ethnicity, and age. Data on reported cases of P&S syphilis were analyzed because these cases represented incidence (i.e., newly acquired infections within the study period) better than cases of latent infection, which were acquired months or years before diagnosis. P&S syphilis rates were calculated by using population denominators from the U.S. Bureau of the Census (1).

During 2001–2002, the rate of P&S syphilis increased 9.1% (from 2.2 cases per 100,000 population in 2001 to 2.4 cases in 2002). In 2002, a total of 6,862 cases of P&S syphilis were reported, an increase of 12.4% over the 6,103 cases reported in 2001, and the rate of P&S syphilis was 3.5 times higher among men than among women (3.8 versus 1.1 cases per 100,000 population) (Table 1). During 2001–2002, the overall male-to-female P&S syphilis rate ratio increased 66.7% (from

FIGURE. Reported rates\* of primary and secondary syphilis, by year and sex, and male-to-female rate ratios — United States, 1981–2002



\* Per 100,000 population.

2.1 to 3.5) (Figure); the male-to-female rate ratio increased among non-Hispanic whites (from 6.0 to 11.0), non-Hispanic blacks (from 1.6 to 2.1), and Hispanics (from 3.7 to 5.0); the rate ratio declined slightly among Asians/Pacific Islanders (from 10.0 to 8.0) and remained unchanged among American Indians/Alaska Natives (AI/ANs) (1.2). The male-to-female rate ratio increased in 27 states and the District of Columbia.

#### INSIDE

- 1120 Health-Related Quality of Life Among Low-Income Persons Aged 45–64 Years — United States, 1995–2001
- 1124 Direct and Indirect Costs of Arthritis and Other Rheumatic Conditions — United States, 1997
- 1127 Diabetes Among Young American Indians — Montana and Wyoming, 2000–2002
- 1129 Investigation of a Ricin-Containing Envelope at a Postal Facility — South Carolina, 2003
- 1132 West Nile Virus Activity — United States, November 13–19, 2003
- 1133 Notice to Readers

\*Data for 2002 are summarized for the reporting year December 30, 2001–December 28, 2002.